Journal
CHEMMEDCHEM
Volume 15, Issue 18, Pages 1682-1690Publisher
WILEY-V C H VERLAG GMBH
DOI: 10.1002/cmdc.202000368
Keywords
ACE2; allostery; coronavirus; drug development; protein dynamics
Categories
Funding
- CONICET
- ANPCyT [PICT PRH-2016-4835, PICT 2016-3525, PICT 2017-0388]
- FOCEM-Mercosur [COF 03/11]
Ask authors/readers for more resources
Angiotensin converting enzyme 2 (ACE2) is the human receptor that interacts with the spike protein of coronaviruses, including the one that produced the 2020 coronavirus pandemic (COVID-19). Thus, ACE2 is a potential target for drugs that disrupt the interaction of human cells with SARS-CoV-2 to abolish infection. There is also interest in drugs that inhibit or activate ACE2, that is, for cardiovascular disorders or colitis. Compounds binding at alternative sites could allosterically affect the interaction with the spike protein. Herein, we review biochemical, chemical biology, and structural information on ACE2, including the recent cryoEM structures of full-length ACE2. We conclude that ACE2 is very dynamic and that allosteric drugs could be developed to target ACE2. At the time of the 2020 pandemic, we suggest that available ACE2 inhibitors or activators in advanced development should be tested for their ability to allosterically displace the interaction between ACE2 and the spike protein.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available